Official Prescription Website | JELMYTO® (mitomycin) for pyelocalyceal solution

Patient Information

Prescribing Information

US Healthcare Professionals US Patients & Caregivers

Patient Information|Prescribing Information|Important Safety Information

Patient lifting shirt showing kidney area

The first and only FDA-approved treatment for low-grade upper tract urothelial cancer (LG-UTUC)

“Who says cancer treatment has to take my kidney?”

How JELMYTO works

Arrow (right) icon

Results with JELMYTO

In a study, JELMYTO has been shown to effectively treat patients with low-grade UTUC.

See the results

Arrow (right) icon

No hospital stay required

JELMYTO is given once a week for 6 weeks as a same-day procedure.

Arrow (right) icon

JELMYTO Patient Brochure

The patient brochure contains important information about what to expect from treatment with JELMYTO. English and Spanish versions are available.

Ask your doctor about JELMYTO, a nonsurgical treatment for low-grade UTUC

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436.

Please click here for JELMYTO Full Prescribing Information, including the Patient Information, for additional information.

Please click here for Full Prescribing Information, Instructions for Pharmacy and Instructions for Administration.